Cepheid Prices $300M of Convertible Senior Notes | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market on Tuesday it has increased the amount of convertible senior notes it is offering and has priced them.

Cepheid raised the offering to $300 million from $250 million announced earlier this week and has granted the initial purchasers an option to purchase an additional $45 million of notes to cover any overallotments. Morgan Stanley and Jefferies are the initial purchasers of the notes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.